The Economic Times

Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% rise in prescriptions over six months. Prices have fallen from over Rs 1 lakh to around Rs 30,000 per cycle, but hospital stocking practices could determine whether patients benefit from lower costs.